Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Shipping warehouse No. 5, Beijing, 100700, China.
Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Shipping warehouse No. 5, Beijing, 100700, China; Institute of Nephrology, and Zhanjiang Key Laboratory of Prevention and Management of Chronic Kidney Disease, Guangdong Medical University, No.57th South Renmin Road, Zhanjiang, Guangdong, 524001, China.
Pharmacol Res. 2019 Apr;142:303-313. doi: 10.1016/j.phrs.2019.02.016. Epub 2019 Feb 19.
The role of gut microbiota in the management of diabetes has been shown. Several current trials are investigating the effect of probiotics and prebiotics, which are widely used to modulate intestinal microbiota, on inflammatory factors and biomarkers of oxidative stress in diabetic patients; however, their findings are controversial. The aim of the current meta-analysis was to evaluate the effects of probiotic and synbiotic supplementation on levels of serum high-sensitivity C-reactive protein (hs-CRP) and biomarkers of oxidative stress in diabetic patients. We searched the PubMed, Web of Science, and The Cochrane Library databases from the inception to October 31, 2018. Randomized controlled trials (RCTs) which reported the effect of probiotics or synbiotics on circulating (serum and plasma) inflammatory marker (hs-CRP) and oxidative stress indicators (malondialdehyde [MDA], glutathione [GSH], nitric oxide [NO], and total antioxidant capacity [TAC]) among patients with diabetes were included. Eligible studies were assessed for risk of bias and subjected to qualitative and quantitative synthesis using either fixed- or random-effects models accounting for clinical heterogeneity. Our meta-analysis identified 16 eligible RCTs (n = 1060). The methodological quality varied across these trials. Pooled data from these trials demonstrated that probiotic and synbiotic consumption significantly decreased hs-CRP level (standardized mean difference [SMD]=-0.38; 95% confidence interval [CI]:-0.51,-0.24; P = 0.000) and MDA (SMD=-0.61; 95% CI: -0.89, -0.32; P = 0.000) in diabetic patients compared to those in subjects receiving placebos. In addition, probiotic and symbiotic supplementation was found to increase TAC (SMD = 0.31; 95% CI: 0.09, 0.52; P = 0.006), NO (SMD, 0.62; 95% CI, 0.25 to 0.99; P = 0.001) and GSH (SMD = 0.41; 95% CI: 0.26, 0.55, P = 0.000) levels. The results of this systematic review and meta-analysis suggest that probiotic and synbiotic supplementation may help to improve biomarkers of inflammation and oxidative stress in diabetic patients. Further studies are needed to develop clinical practice guidelines for the management of inflammation and oxidative stress in these patients.
肠道微生物群在糖尿病管理中的作用已经得到证实。目前有几项临床试验正在研究益生菌和益生元的作用,它们被广泛用于调节肠道微生物群,以观察它们对糖尿病患者炎症因子和氧化应激生物标志物的影响;然而,他们的发现存在争议。本荟萃分析的目的是评估益生菌和合生制剂补充对糖尿病患者血清高敏 C 反应蛋白(hs-CRP)和氧化应激生物标志物水平的影响。我们检索了 PubMed、Web of Science 和 The Cochrane Library 数据库,检索时间从 1970 年 1 月至 2018 年 10 月 31 日。纳入了报告益生菌或合生制剂对糖尿病患者循环(血清和血浆)炎症标志物(hs-CRP)和氧化应激指标(丙二醛[MDA]、谷胱甘肽[GSH]、一氧化氮[NO]和总抗氧化能力[TAC])影响的随机对照试验(RCT)。纳入的研究评估了偏倚风险,并使用固定或随机效应模型进行定性和定量综合分析,以考虑临床异质性。我们的荟萃分析确定了 16 项符合条件的 RCT(n=1060)。这些试验的方法学质量存在差异。这些试验的汇总数据表明,与安慰剂组相比,益生菌和合生制剂的摄入显著降低了 hs-CRP 水平(标准化均数差[SMD]=-0.38;95%置信区间[CI]:-0.51,-0.24;P=0.000)和 MDA(SMD=-0.61;95% CI:-0.89,-0.32;P=0.000)。此外,益生菌和合生制剂补充剂可增加 TAC(SMD=0.31;95% CI:0.09,0.52;P=0.006)、NO(SMD,0.62;95% CI,0.25 至 0.99;P=0.001)和 GSH(SMD=0.41;95% CI:0.26,0.55,P=0.000)水平。本系统评价和荟萃分析的结果表明,益生菌和合生制剂补充剂可能有助于改善糖尿病患者的炎症和氧化应激生物标志物。需要进一步的研究来为这些患者的炎症和氧化应激管理制定临床实践指南。